Abstract
On November 13, 2015, the FDA granted accelerated approval to osimertinib (TAGRISSO; AstraZeneca), a breakthrough therapy-designated drug for the trea......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
